Skip to content
Find a Provider
Sarah L. Spitznogle, Pharm.D.

Sarah L. Spitznogle, Pharm.D.

No ratings currently available, see text in Ratings section below for explanation.

Contact

Call Center (585) 276-3000

About Me

Sarah L. Spitznogle PharmD, BCIDP received her doctorate of pharmacy from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed her PGY1 Acute Care Pharmacy Residency at UPMC Presbyterian in Pittsburgh PA, and her PGY2 Infectious Diseases Pharmacy Residency at the U...
Sarah L. Spitznogle PharmD, BCIDP received her doctorate of pharmacy from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed her PGY1 Acute Care Pharmacy Residency at UPMC Presbyterian in Pittsburgh PA, and her PGY2 Infectious Diseases Pharmacy Residency at the University of Texas MD Anderson Cancer Center. She began her career in Dallas TX as a Clinical Pharmacy Specialist in Transplant Infectious Diseases, where she established the Transplant Infectious Diseases Pharmacy service line at UT Southwestern Medical Center. She then relocated and transitioned into her current role as a Clinical Infectious Diseases Pharmacy Specialist at the University of Rochester Medical Center.

Dr. Spitznogle serves as a preceptor for APPE students, PGY-1 and PGY-2 Pharmacy residents. Her academic interests include mechanisms of gram-negative resistance, antimicrobial pharmacokinetics/pharmacodynamics, and infections in the immunocompromised host. She is also an active member in the Society of Infectious Diseases Pharmacists (SIDP).

Credentials

Residency & Fellowship

PGY2 Infectious Diseases Pharmacy Residency, The University of Texas MD Anderson Cancer Center, Houston TX 2019 - 2020

PGY1 Acute Care Pharmacy Residency, UPMC Presbyterian, Pittsburgh PA 2018 - 2019

Education

Doctor of Pharmacy | University at Buffalo School of Pharmacy and Pharmaceutical Sciences. 2018

Publications

Journal Articles

Genetic determinants underlying the progressive phenotype of ?-lactam/?-lactamase inhibitor resistance in .

Shropshire WC, Amiji H, Bremer J, Selvaraj Anand S, Strope B, Sahasrabhojane P, Gohel M, Aitken S, Spitznogle S, Zhan X, Kim J, Greenberg DE, Shelburne SA

Microbiology spectrum.. 2023 December 1211 (6):e0222123. Epub 10/06/2023.

Significant Publications on Infectious Diseases Pharmacotherapy in 2019.

Hendrickson JA, Spitznogle SL, Gonzales-Luna AJ, Babic JT, Britt RS, Knight JM, Pham SN, McDaneld PM

Journal of pharmacy practice.. 2021 October 34 (5):800-813. Epub 09/16/2020.

An Overview of the Treatment of Less Common Non-Lactose-Fermenting Gram-Negative Bacteria.

Spencer HK, Spitznogle SL, Borjan J, Aitken SL

Pharmacotherapy.. 2020 September 40 (9):936-951. Epub 08/14/2020.

A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).

Shafiq I, Bulman ZP, Spitznogle SL, Osorio JE, Reilly IS, Lesse AJ, Parameswaran GI, Mergenhagen KA, Tsuji BT

Infectious diseases.. 2017 May 49 (5):410-416. Epub 01/24/2017.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.